{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:02:06Z","timestamp":1792789326346,"version":"4.5.0"},"reference-count":28,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Johnson &amp; Johnson Innovative Medicine"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Most patients with non-small-cell lung cancer (NSCLC) present with advanced\/metastatic disease at diagnosis, and molecular profiling is critical in guiding treatment decisions. This retrospective cohort study aimed to characterize EGFR mutations (EGFRm) in advanced\/metastatic NSCLC patients, treatment patterns, and real-world outcomes. Adults diagnosed between 2018 and 2021 and treated at a Comprehensive Care Center were included. Time-to-event outcomes were analyzed using the Kaplan\u2013Meier method. A total of 110 patients were included, with a median age of 69.0 years (range, 37\u201393), 76.4% female, and 83.2% non-smokers. About 97.3% had adenocarcinomas, with 93.6% at stage IV, 40.9% with \u2265 three metastatic sites (brain metastases in 24.5%), 33.6% ECOG 2\u20134, and 58.2% with an EGFR exon-19 deletion. A minority started supportive care or curative-intent treatment, and 81.8% underwent first-line palliative systemic therapy (TKIs, 91.1%; chemotherapy, 8.9%). Median real-world overall survival (rwOS) was 18.9 months (95% CI, 13.8\u201328.1). Worse rwOS was observed in patients with ECOG 2\u20134 versus ECOG 0\u20131 (10.3 vs. 22.8 months; HR 1.82, 95% CI 1.17\u20132.85; p = 0.008) and in patients with exon-21 L858R versus exon 19 deletions (15.8 vs. 24.2 months; HR 1.59, 95% CI 1.00\u20132.54; p = 0.048). In patients treated with palliative systemic treatment, median progression-free survival was 10.9 months (95% CI, 8.8\u201313.6). This study provides important insights regarding real-world characteristics, treatment patterns, and outcomes from a cohort of EGFRm advanced\/metastatic NSCLC patients.<\/jats:p>","DOI":"10.3390\/curroncol32080414","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T07:54:26Z","timestamp":1753343666000},"page":"414","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Characterization of the Population, Treatment Patterns, and Outcomes of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor Mutation (EGFRm): A Retrospective Cohort Study from IPO Porto"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2955-0551","authenticated-orcid":false,"given":"Ana","family":"Rodrigues","sequence":"first","affiliation":[{"name":"Medical Oncology Department, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Pina","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Calisto","sequence":"additional","affiliation":[{"name":"Outcomes Research Lab, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal"},{"name":"Group of Epidemiology, Results, Economy and Management in Oncology, GEREMO Research Center, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal"},{"name":"Porto Comprehensive Cancer Center (Porto.CCC) & RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7015-242X","authenticated-orcid":false,"given":"Pedro","family":"Leite-Silva","sequence":"additional","affiliation":[{"name":"Group of Epidemiology, Results, Economy and Management in Oncology, GEREMO Research Center, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal"},{"name":"Porto Comprehensive Cancer Center (Porto.CCC) & RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal"},{"name":"Epidemiology Department, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Medeiros","sequence":"additional","affiliation":[{"name":"Outcomes Research Lab, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal"},{"name":"Group of Epidemiology, Results, Economy and Management in Oncology, GEREMO Research Center, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal"},{"name":"Porto Comprehensive Cancer Center (Porto.CCC) & RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5079-1677","authenticated-orcid":false,"given":"Catarina","family":"Silva","sequence":"additional","affiliation":[{"name":"Institute for Evidence Based Health (ISBE), 1649-028 Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Sofia","family":"Silva","sequence":"additional","affiliation":[{"name":"Group of Epidemiology, Results, Economy and Management in Oncology, GEREMO Research Center, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal"},{"name":"Porto Comprehensive Cancer Center (Porto.CCC) & RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcia","family":"Redondo","sequence":"additional","affiliation":[{"name":"Group of Epidemiology, Results, Economy and Management in Oncology, GEREMO Research Center, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal"},{"name":"Porto Comprehensive Cancer Center (Porto.CCC) & RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6140-7363","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Ramalho-Carvalho","sequence":"additional","affiliation":[{"name":"J&J Innovative Medicine, 2740-298 Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana Ferreira","family":"Santos","sequence":"additional","affiliation":[{"name":"J&J Innovative Medicine, 2740-298 Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7690-9830","authenticated-orcid":false,"given":"Maria Jos\u00e9","family":"Bento","sequence":"additional","affiliation":[{"name":"Group of Epidemiology, Results, Economy and Management in Oncology, GEREMO Research Center, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal"},{"name":"Porto Comprehensive Cancer Center (Porto.CCC) & RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal"},{"name":"Epidemiology Department, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"ref_1","unstructured":"Global Cancer Observatory (GLOBOCAN) (2025, February 05). World Fact Sheet 2022. Available online: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/900-world-fact-sheet.pdf."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2021.10.020","article-title":"Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations","volume":"162","author":"Bazhenova","year":"2021","journal-title":"Lung Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40291-021-00563-1","article-title":"Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis","volume":"26","author":"Melosky","year":"2022","journal-title":"Mol. Diagn. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"78985","DOI":"10.18632\/oncotarget.12587","article-title":"The prevalence of EGFR mutation in patients with non-small cell lung cancer: A systematic review and meta-analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11523-022-00868-z","article-title":"Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis","volume":"17","author":"Murton","year":"2022","journal-title":"Target. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"FLAURA Investigators. Overall Survival with Osimertinib in Untreated EGFR-Mutated Advanced, NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41571-024-00971-2","article-title":"The changing treatment landscape of EGFR-mutant non-small-cell lung cancer","volume":"22","author":"Zhou","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJMc2414705","article-title":"Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC","volume":"392","author":"Rosenfeld","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"FLAURA2 Investigators. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-019-0038-9","article-title":"Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer","volume":"4","author":"Vyse","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00228-015-1966-0","article-title":"Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: A meta-analysis","volume":"72","author":"Sheng","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e432516","DOI":"10.1200\/EDBK_432516","article-title":"New Treatment Options for Patients With Oncogene-Addicted Non-Small Cell Lung Cancer Focusing on EGFR-Mutant Tumors","volume":"44","author":"Saw","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S208","DOI":"10.1016\/j.jtho.2021.01.112","article-title":"Underdiagnosis of EGFR exon 20 insertion mutation variants: Estimates from NGS-based real-world datasets","volume":"16","author":"Bauml","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"108412","DOI":"10.1016\/j.lungcan.2025.108412","article-title":"EGFR testing practices, treatment choice and clinical outcomes in advanced NSCLC in a real-world setting: A retrospective analysis of a US-based electronic health records database","volume":"201","author":"Subramanian","year":"2025","journal-title":"Lung Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Hochmair, M.J., Unk, M., Spasic, J., Ceri\u0107, T., Konsoulova, A., Dediu, M., Bogos, K., Hegmane, A., Oselin, K., and Stojiljkovic, M. (2024). Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: Reimbursement, diagnostic procedures, and treatment availability. BMC Proc., 18.","DOI":"10.1186\/s12919-023-00287-6"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"147","author":"Altman","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"ref_19","first-page":"93","article-title":"The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1158\/1078-0432.CCR-22-0471","article-title":"Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non-Small Cell Lung Cancer Trials Using Real-World Data","volume":"28","author":"Ton","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.19.00013","article-title":"Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non-Small-Cell Lung Cancer Data Set","volume":"3","author":"Griffith","year":"2019","journal-title":"JCO Clin. Cancer Inform."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Burnett, H., Emich, H., Carroll, C., Stapleton, N., Mahadevia, P., and Li, T. (2021). Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0247620"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e70369","DOI":"10.1002\/cam4.70369","article-title":"Patterns of Treatment and Real-World Outcomes of Patients With Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT Study","volume":"14","author":"Liu","year":"2025","journal-title":"Cancer Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jtho.2023.01.086","article-title":"Distribution and Detectability of EGFR Exon 20 Insertion Variants in NSCLC","volume":"18","author":"Ou","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2217\/fon-2020-0951","article-title":"Benefits and limitations of real-world evidence: Lessons from EGFR mutation-positive non-small-cell lung cancer","volume":"17","author":"Nazha","year":"2021","journal-title":"Future Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.jtho.2023.06.017","article-title":"Genomic Alterations and the Incidence of Brain Metastases in Advanced and Metastatic NSCLC: A Systematic Review and Meta-Analysis","volume":"18","author":"Gillespie","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"ref_27","first-page":"100765","article-title":"Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator\u2019s Consortium Registry Analysis","volume":"6","author":"Stalker","year":"2024","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"100592","DOI":"10.1016\/j.lanepe.2023.100592","article-title":"Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: A retrospective, nationwide registry study","volume":"27","author":"Gijtenbeek","year":"2023","journal-title":"Lancet Reg. Health Eur."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/8\/414\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:15:00Z","timestamp":1760033700000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/8\/414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":28,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["curroncol32080414"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32080414","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]}}}